AZUR-1 trial, a single arm trial of Jemperli (dostarlimab) in patients with stage 2/3 mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer, met its primary objective, showing a meaningful and sustained clinical complete response rate at 12 months.
The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.
